open access

Vol 9, No 5 (2004)
Original papers
Published online: 2004-01-01
Submitted: 2004-03-15
Get Citation

Clinical value of molecular changes in ovarian carcinoma

Jolanta Kupryjańczyk
DOI: 10.1016/S1507-1367(04)71021-4
·
Rep Pract Oncol Radiother 2004;9(5):149-155.

open access

Vol 9, No 5 (2004)
Original papers
Published online: 2004-01-01
Submitted: 2004-03-15

Abstract

Studies carried out on cell lines and ovarian cancer xenografts have indicated that some disturbances of the expression of some groups of genes in cancer cells have a role in the efficacy of chemotherapy, including the response to given groups of drugs. Cisplatin is a DNA-da-maging agent. On the basis of the data obtained from cell lines the level of the expression of TP53, BCL and BAX proteins affects the response of the ovarian cancer to cisplatin, however this effect has not been confirmed in clinical studies. In the last few years, in the framework of a multi-centre project, we have investigated a group of 233 patients with ovarian cancer treated with cisplatin regimen (cisplatin plus cyclophos-phamide). We have shown that ovarian carcinomas with TP53 protein accumulation (TP53+) and those without accumulation (TP53-) constitute separate biological groups. In our studies the TP53 status had an impact on the clinical value of other proteins such as BAX and BCL-2, as well as of some clinical factors, eg. residual tumor size or clinical stage. BCL-2 expression had a negative influence on complete remission only in the TP53(-) group. On the other hand, the risk of a relapse was lower for the higher BAX expression in the TP53 (+) group. Now we have embarked on similar studies on a group of patients treated with taxanes. In the future, the evaluation of molecular markers may provide a basis for a more individualised chemotherapy of ovarian cancer patients.

Abstract

Studies carried out on cell lines and ovarian cancer xenografts have indicated that some disturbances of the expression of some groups of genes in cancer cells have a role in the efficacy of chemotherapy, including the response to given groups of drugs. Cisplatin is a DNA-da-maging agent. On the basis of the data obtained from cell lines the level of the expression of TP53, BCL and BAX proteins affects the response of the ovarian cancer to cisplatin, however this effect has not been confirmed in clinical studies. In the last few years, in the framework of a multi-centre project, we have investigated a group of 233 patients with ovarian cancer treated with cisplatin regimen (cisplatin plus cyclophos-phamide). We have shown that ovarian carcinomas with TP53 protein accumulation (TP53+) and those without accumulation (TP53-) constitute separate biological groups. In our studies the TP53 status had an impact on the clinical value of other proteins such as BAX and BCL-2, as well as of some clinical factors, eg. residual tumor size or clinical stage. BCL-2 expression had a negative influence on complete remission only in the TP53(-) group. On the other hand, the risk of a relapse was lower for the higher BAX expression in the TP53 (+) group. Now we have embarked on similar studies on a group of patients treated with taxanes. In the future, the evaluation of molecular markers may provide a basis for a more individualised chemotherapy of ovarian cancer patients.

Get Citation

Keywords

ovarian cancer; TP53; BCL-2; BAX; cisplatin

About this article
Title

Clinical value of molecular changes in ovarian carcinoma

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 9, No 5 (2004)

Pages

149-155

Published online

2004-01-01

DOI

10.1016/S1507-1367(04)71021-4

Bibliographic record

Rep Pract Oncol Radiother 2004;9(5):149-155.

Keywords

ovarian cancer
TP53
BCL-2
BAX
cisplatin

Authors

Jolanta Kupryjańczyk

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl